Table 1.
Clinical features of the patients with multiple sclerosis
| Feature | Value |
|
|---|---|---|
| Natalizumab (n = 64 MS patients) | Control (n = 35 MS patients) | |
| Median age | 40 | 44 |
| Sex ratio (female to male) | 1.74 | 1.69 |
| Median Expanded Disability Status Scale score (range) | 3.5 (1–7.5) | 3.5 (1–6.5) |
| Duration of the disease ± SD (yrs) | 11.4 ± 5.2 | 10 ± 4.8 |
| No. (range) of natalizumab infusions | 24 (1–48) | |
| No. of patients sampled twice (interval between 1st and 2nd sample) | 41 (10.6 ± 2.8 mo) | |
| No. of patients sampled 3 times or more (interval between 2nd and 3rd sample) | 6 (10 ± 0.3 mo) | |